ç¤ºç¯„ITP

2025å¹´2æœˆ4æ—¥

ä¸‹åˆ 07:55

Â 

- **<span class="mark">immune thrombocytopenic purpura(ITP)</span>**ï¼š

  - å®šç¾©ï¼šæ‰¾ä¸å‡ºåŸå› çš„isolated thrombocytopenia(\< 100,000/mm3)

    - Newly diagnosed ITPï¼šè¨ºæ–·å¾Œå‰ 3 å€‹æœˆ

    - Persistent ITPï¼šæŒçºŒ 3-12 å€‹æœˆ

    - Chronic ITPï¼šæŒçºŒ \> 12 å€‹æœˆ

  - æµè¡Œç—…å­¸ï¼š

    - å…’ç«¥ï¼š

      - \< 5æ­²prevalenceæœ€é«˜

      - Self-limitingï¼š**ç—…æ¯’æ„ŸæŸ“**å¾Œæ¶ˆå¤±

      - **80%åœ¨12å€‹æœˆå…§æ¶ˆé€€**

    - æˆäººï¼š

      - \>55æ­²prevalenceæœ€é«˜

      - 80%ç™¼å±•æˆ[Chronic ITP](onenote:#ğŸ©ºç–¾ç—…|å‡è¡€ç›¸é—œç–¾ç—…&section-id={F4BD5699-E3A3-4D0A-995D-58AB93A64C6C}&page-id={50AE51A6-0587-42F2-90A2-8CE646200224}&object-id={DFC3F6F1-EE87-4630-9740-8AFD7903EA5D}&25&base-path=https://d.docs.live.net/56ce32fba64785ca/è‡¨åºŠç­†è¨˜/HEMA%5eJ%20ONCO.one)

      - 25% ç”±CBCæª¢æŸ¥å¶ç„¶ç™¼ç¾

  - ç—…ç”Ÿç†ï¼šèº«é«”ä¸­ç”¢ç”Ÿ**è¡€å°æ¿æŠ—é«”(Anti-PLT Ab)**(é€šå¸¸æ˜¯IgGç›´æ¥æ¥ä¸ŠPltè¡¨é¢è›‹ç™½æ”»æ“Š)â†’é€åˆ°è‚è„¾è™•ç†â†’**éª¨é«“megakaryocyteã€Pltè£½é€ å¢åŠ (çµ•å¤§å¤šæ•¸) \[[Type 2éæ•](onenote:åŸºç¤ç”Ÿç†.one#éæ•åæ‡‰&section-id={EB04CCEF-7970-4EE5-96FE-D4EF960010B4}&page-id={B444B81C-7EE9-4EAD-9D6E-6224BFFE2E9E}&object-id={4D15FA70-8C1E-4AC6-AB70-EB0D0ACC2547}&67&base-path=https://d.docs.live.net/56ce32fba64785ca/è‡¨åºŠç­†è¨˜)\]**

  - ç—…å› ï¼š

    - **Primaryï¼šidiopathic(æœ€å¸¸è¦‹)**

    - Secondaryï¼š

      - Autoimmuneï¼šSLEã€Anti-phospholipid syndrome

      - æ„ŸæŸ“ï¼šHIVã€HCVã€EBVã€VZV

      - æƒ¡æ€§è…«ç˜¤ï¼šLymphomaã€Leukemia(ç‰¹åˆ¥æ˜¯CLL)

      - è—¥ç‰©ï¼šquinine, beta-lactam antibiotics, carbamazepine, heparin, vaccines, linezolid, sulfonamides, vancomycin, TMP-SMX, antiepileptics

  - è‡¨åºŠè¡¨ç¾ï¼š**å¥½ç™¼ç—…æ¯’æ„ŸæŸ“å¾Œ1-4é€±**

    - æœ€å¸¸è¦‹ï¼šç„¡ç—‡ç‹€ã€ç„¡è„¾è‡Ÿè…«å¤§

    - è¼•å¾®è¡¨çš®ã€é»è†œå‡ºè¡€

  - è¨ºæ–·ï¼š**æ’é™¤æ€§è¨ºæ–·**

    - å…ˆæ’é™¤å…¶ä»–æ¬¡ç™¼æ€§åŸå› ï¼ŒAnti-plt Abä½æ•æ„Ÿåº¦ã€ä½å°ˆä¸€æ€§

  - æ²»ç™‚ï¼šè¡€å°æ¿**\<50000å‡ºè¡€åš´é‡**ï¼Œ**æˆ–\<30000æ‰éœ€æ²»ç™‚**

    - ç¬¬ä¸€ç·šè—¥ç‰©ï¼š**é¡å›ºé†‡**(æ²»ç™‚åˆ°Plt \> 50000)

    - åš´é‡å‡ºè¡€ç—…äººè€ƒæ…®åˆä½µIVIG

      - **æ˜é¡¯æ€¥æ€§å‡ºè¡€å¯è¼¸è¡€å°æ¿ï¼Œè‹¥å‡ºè¡€ä»ä¸æ­¢å¯è€ƒæ…®Recombinant factor VIIa**

    - å…¶ä»–æ²»ç™‚ï¼š**rituximab**ã€TPO receptor agonist(**Romiplostimã€Eltrombopag**)ã€Splenectomy(æ²»ç™‚ç„¡æ•ˆè¶…é1å¹´)ã€ Danazolã€Azathioprineã€Cyclophosphomideã€MMFã€Cyclosporin
